PL2900664T3 - Postacie krystaliczne pochodnych dihydropirymidyny - Google Patents

Postacie krystaliczne pochodnych dihydropirymidyny

Info

Publication number
PL2900664T3
PL2900664T3 PL13841041T PL13841041T PL2900664T3 PL 2900664 T3 PL2900664 T3 PL 2900664T3 PL 13841041 T PL13841041 T PL 13841041T PL 13841041 T PL13841041 T PL 13841041T PL 2900664 T3 PL2900664 T3 PL 2900664T3
Authority
PL
Poland
Prior art keywords
crystalline forms
dihydropyrimidine derivatives
dihydropyrimidine
derivatives
crystalline
Prior art date
Application number
PL13841041T
Other languages
English (en)
Polish (pl)
Inventor
Yingjun Zhang
Qingyun REN
Xinchang LIU
Chaolei WANG
Tianming Wang
Siegfried Goldmann
Original Assignee
Sunshine Lake Pharma Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co., Ltd. filed Critical Sunshine Lake Pharma Co., Ltd.
Publication of PL2900664T3 publication Critical patent/PL2900664T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL13841041T 2012-09-27 2013-09-27 Postacie krystaliczne pochodnych dihydropirymidyny PL2900664T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201210369019 2012-09-27
CN201310117076 2013-04-04
PCT/CN2013/084383 WO2014048355A1 (en) 2012-09-27 2013-09-27 Crystalline forms of dihydropyrimidine derivatives
EP13841041.0A EP2900664B1 (en) 2012-09-27 2013-09-27 Crystalline forms of dihydropyrimidine derivatives

Publications (1)

Publication Number Publication Date
PL2900664T3 true PL2900664T3 (pl) 2018-06-29

Family

ID=50355923

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13841041T PL2900664T3 (pl) 2012-09-27 2013-09-27 Postacie krystaliczne pochodnych dihydropirymidyny

Country Status (20)

Country Link
US (1) US9403814B2 (enExample)
EP (1) EP2900664B1 (enExample)
JP (1) JP6310923B2 (enExample)
KR (1) KR20150060610A (enExample)
CN (3) CN103724339B (enExample)
AU (1) AU2013324779B2 (enExample)
BR (1) BR112015002979B8 (enExample)
CA (1) CA2881260C (enExample)
DK (1) DK2900664T3 (enExample)
ES (1) ES2660642T3 (enExample)
HU (1) HUE037285T2 (enExample)
MX (1) MX362829B (enExample)
MY (1) MY171497A (enExample)
PL (1) PL2900664T3 (enExample)
PT (1) PT2900664T (enExample)
RU (1) RU2646599C2 (enExample)
SG (1) SG11201500145TA (enExample)
TW (1) TWI561520B (enExample)
WO (1) WO2014048355A1 (enExample)
ZA (1) ZA201500290B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2881322A1 (en) * 2012-09-10 2014-03-13 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CA3004147C (en) * 2015-11-04 2019-09-10 Qilu Pharmaceutical Co., Ltd. Crystal form, preparation method and intermediate of dihydropyrido ring compound
WO2017198201A1 (en) * 2016-05-19 2017-11-23 Sunshine Lake Pharma Co., Ltd. Crystalline form, salt and complex of dihydropyrimidine derivative, and uses thereof in medicine
CN107722109B (zh) * 2016-08-11 2020-12-18 广东东阳光药业有限公司 作为丙型肝炎病毒抑制剂的晶型
US9856232B1 (en) * 2017-06-20 2018-01-02 King Saud University Dihydropyrimidinone derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR043880A1 (es) 2003-04-22 2005-08-17 Solvay Pharm Gmbh Mesilato acido de 4-(4.trans-hidroxiciclohexil) amino-2-fenil-7h-pirrolo (2,3-d) pirimidina y sus formas polimorfas
WO2008154819A1 (fr) 2007-06-18 2008-12-24 Zhang, Zhongneng Thiazolyl-dihydropyrimidines à substitution carbéthoxy
PT2514750E (pt) * 2007-06-18 2014-01-23 Sunshine Lake Pharma Co Ltd Tiazolil dihidropirimidinas substituídas com bromo-fenilo
CN101328170B (zh) 2007-06-18 2011-09-14 张中能 一种氟苯基-取代噻唑二氢嘧啶
WO2008154820A1 (fr) 2007-06-18 2008-12-24 Zhang, Zhongneng Thiazolyl-dihydropyrimidines à substitution carbéthoxy
WO2010069147A1 (zh) * 2008-12-17 2010-06-24 张中能 二氢嘧啶类化合物、其组合物及其应用
CN101744823B (zh) * 2008-12-17 2013-06-19 广东东阳光药业有限公司 一种二氢嘧啶类化合物的固体分散体及其药用制剂

Also Published As

Publication number Publication date
WO2014048355A1 (en) 2014-04-03
RU2015114085A (ru) 2016-11-20
CN104945394B (zh) 2017-12-05
CN104945394A (zh) 2015-09-30
CN103724339B (zh) 2015-10-14
AU2013324779A1 (en) 2015-02-05
BR112015002979A2 (pt) 2017-07-04
HUE037285T2 (hu) 2018-08-28
MX2015004115A (es) 2016-01-20
JP2015531354A (ja) 2015-11-02
AU2013324779B2 (en) 2015-10-08
EP2900664A4 (en) 2016-03-09
CA2881260A1 (en) 2014-04-03
US20150239877A1 (en) 2015-08-27
DK2900664T3 (en) 2018-02-05
TW201412732A (zh) 2014-04-01
MX362829B (es) 2019-02-14
EP2900664B1 (en) 2017-12-13
BR112015002979B1 (pt) 2020-12-22
HK1207081A1 (en) 2016-01-22
TWI561520B (en) 2016-12-11
KR20150060610A (ko) 2015-06-03
ES2660642T3 (es) 2018-03-23
PT2900664T (pt) 2018-03-02
CN103694234A (zh) 2014-04-02
CA2881260C (en) 2020-10-27
CN103724339A (zh) 2014-04-16
BR112015002979B8 (pt) 2022-03-03
MY171497A (en) 2019-10-15
US9403814B2 (en) 2016-08-02
JP6310923B2 (ja) 2018-04-11
EP2900664A1 (en) 2015-08-05
SG11201500145TA (en) 2015-02-27
ZA201500290B (en) 2016-10-26
RU2646599C2 (ru) 2018-03-06

Similar Documents

Publication Publication Date Title
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
HUE047354T2 (hu) Ivacaftor deuterizált származékai
PL3235812T3 (pl) Deuterowane pochodne iwakaftoru
PL2753615T3 (pl) Pochodne benzonitrylowe jako inhibitory kinazowe
IL230976A (en) Crystalline forms of Czebitaxel
PL2912041T3 (pl) Pochodne tetrahydropirolotiazyny stanowiące inhibitory BACE
SG11201406860SA (en) Quinazolinedione derivative
GB201501016D0 (en) Preparation of 18F-fluciclovine
IL237458A0 (en) crystalline compounds
ZA201500290B (en) Crystalline forms of dihydropyrimidine derivatives
SG11201404325VA (en) Pyrimidooxazocine derivatives as mtor - inhibitors
IL237862A0 (en) Methods to reduce the formation of scale
EP2680843A4 (en) DERIVATIVES OF PYRAZOLSUBSTITUTED AMINO-HETEROARYL COMPOUNDS
ZA201502350B (en) Solid form of hihydro-pyrido-oxazine derivative
SG11201503051QA (en) Formulations of pyrimidinedione derivative compounds
IL230977A (en) A crystalline form of relapaldib
PL2709584T3 (pl) Zastosowanie sensoryczne pochodnych 6-cyklopentylidenoheksanu
IL237824B (en) Crystalline polymorphic form of ulipristal acetate
HUE036665T2 (hu) Dihidro-pirido-oxazin származék szilárd formái
TWM433525U (en) Structure of calorifier